| Are markers of systemic inflammation good prognostic indicators in colorectal cancer? S Rossi, M Basso, A Strippoli, G Schinzari, E D'Argento, M Larocca, ... Clinical colorectal cancer 16 (4), 264-274, 2017 | 116 | 2017 |
| Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? A Inno, M Di Salvatore, T Cenci, M Martini, A Orlandi, A Strippoli, ... Clinical colorectal cancer 10 (4), 325-332, 2011 | 110 | 2011 |
| Muscle mass, assessed at diagnosis by L3-CT scan as a prognostic marker of clinical outcomes in patients with gastric cancer: a systematic review and meta-analysis E Rinninella, M Cintoni, P Raoul, C Pozzo, A Strippoli, E Bria, G Tortora, ... Clinical Nutrition 39 (7), 2045-2054, 2020 | 108 | 2020 |
| Hormone receptor status and HER2 expression in primary breast cancer compared with synchronous axillary metastases or recurrent metastatic disease S Rossi, M Basso, A Strippoli, V Dadduzio, E Cerchiaro, R Barile, ... Clinical breast cancer 15 (5), 307-312, 2015 | 96 | 2015 |
| Effects of nutritional interventions on nutritional status in patients with gastric cancer: A systematic review and meta-analysis of randomized controlled trials E Rinninella, M Cintoni, P Raoul, C Pozzo, A Strippoli, E Bria, G Tortora, ... Clinical nutrition ESPEN 38, 28-42, 2020 | 74 | 2020 |
| INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI … F Pietrantonio, A Raimondi, S Lonardi, S Murgioni, GG Cardellino, ... Journal of Clinical Oncology 41 (4_suppl), 358-358, 2023 | 60 | 2023 |
| c-MYC expression is a possible keystone in the colorectal cancer resistance to EGFR inhibitors A Strippoli, A Cocomazzi, M Basso, T Cenci, R Ricci, F Pierconti, ... Cancers 12 (3), 638, 2020 | 59 | 2020 |
| Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer IV Zurlo, M Schino, A Strippoli, MA Calegari, A Cocomazzi, A Cassano, ... Cancer Immunology, Immunotherapy 71 (1), 45-55, 2022 | 58 | 2022 |
| Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A bidirectional approach for gastric cancer peritoneal metastasis A Di Giorgio, CA Schena, MA El Halabieh, C Abatini, E Vita, A Strippoli, ... Surgical Oncology 34, 270-275, 2020 | 49 | 2020 |
| TremelImumab and durvalumab combination for the non-operative management (NOM) of microsatellite instability (MSI)-high resectable gastric or gastroesophageal junction cancer … A Raimondi, F Palermo, M Prisciandaro, M Aglietta, L Antonuzzo, G Aprile, ... Cancers 13 (11), 2839, 2021 | 41 | 2021 |
| KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients M Basso, A Strippoli, A Orlandi, M Martini, MA Calegari, G Schinzari, ... British journal of cancer 108 (1), 115-120, 2013 | 38 | 2013 |
| Does sarcopenia affect outcome in patients with non-small-cell lung cancer harboring EGFR mutations? S Rossi, V Di Noia, L Tonetti, A Strippoli, M Basso, G Schinzari, ... Future Oncology 14 (10), 919-926, 2018 | 37 | 2018 |
| Results of the observational prospective RealFLOT study E Giommoni, D Lavacchi, G Tirino, L Fornaro, F Iachetta, C Pozzo, ... BMC cancer 21, 1-11, 2021 | 30 | 2021 |
| Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis S Rossi, E D’Argento, M Basso, A Strippoli, V Dadduzio, E Cerchiaro, ... Molecular diagnosis & therapy 20, 55-63, 2016 | 27 | 2016 |
| Body composition changes in gastric cancer patients during preoperative FLOT therapy: preliminary results of an Italian cohort study E Rinninella, A Strippoli, M Cintoni, P Raoul, R Vivolo, M Di Salvatore, ... Nutrients 13 (3), 960, 2021 | 25 | 2021 |
| Treatment options for EGFR T790M-negative EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer S Corallo, E D’Argento, A Strippoli, M Basso, S Monterisi, S Rossi, ... Targeted oncology 12, 153-161, 2017 | 25 | 2017 |
| Conversion chemotherapy for technically unresectable colorectal liver metastases: a retrospective, STROBE-compliant, single-center study comparing chemotherapy alone and … M Basso, V Dadduzio, F Ardito, P Lombardi, A Strippoli, M Vellone, ... Medicine 95 (20), e3722, 2016 | 24 | 2016 |
| Maintenance hormonal and chemotherapy treatment in metastatic breast cancer: a systematic review S Rossi, G Schinzari, M Basso, A Strippoli, V Dadduzio, E D’Argento, ... Future Oncology 12 (10), 1299-1307, 2016 | 23 | 2016 |
| ERCC1 induction after oxaliplatin exposure may depend on KRAS mutational status in colorectal cancer cell line: in vitro veritas A Orlandi, M Di Salvatore, C Bagalà, M Basso, A Strippoli, F Plastino, ... Journal of Cancer 6 (1), 70, 2015 | 23 | 2015 |
| Gastrointestinal stromal tumors (GISTs) and second malignancies: a novel “sentinel tumor”? A monoinstitutional, STROBE-compliant observational analysis MG Rodriquenz, S Rossi, R Ricci, M Martini, M Larocca, A Dipasquale, ... Medicine 95 (38), e4718, 2016 | 22 | 2016 |
